Appendix Table 2.
Sensitivity of T-SPOT.TB among Patients with Active Tuberculosis (TB)
| Study, Year (Reference) |
Industry Supported?* |
Sample | Setting | Patients with Active (Culture-Confirmed) TB, n (%) | HIV-Positive Patients, % | T-SPOT.TB Result, n (%) | Sensitivity of TST | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Indeterminate† | Cutoff Value | Patients, n/n (%) | ||||||
| Meier et al., 2005 (29) | Yes | Adults | Germany | 73 (86) | 2 | 70 (97) | 2 (3) | 1 (1) | NR | 40/45 (89) |
| Lee et al., 2006 (11) | Yes | Predominantly adults |
South Korea | 87 (63) | 0 | 83 (95) | 4 (5) | 0 (0) | 10 mm | 58/87 (67) |
| Goletti et al., 2006 (13) | Yes | Predominantly adults |
Italy | 23 (100) | 0 | 21 (91) | 2 (9) | 0 (0) | NR | NR |
| Ferrara et al., 2006 (12) | No | Predominantly adults |
Italy | 24 (NR) | NR | 20 (83) | 4 (17) | 0 (0) | Risk stratified | 14/20 (70) |
| Jafari et al., 2006 (30) | Yes | Predominantly adults |
Germany | 12 (67) | NR | 12 (100) | 0 (0) | 0 (0) | 10 mm | 10/12 (83) |
| Domínguez et al., 2008 (23) | Yes | Adults and children‡ |
Spain | 42 (NR) | 0 | 36 (86) | 3 (7) | 3 (7) | 5 mm | 40/42 (95) |
| Kang et al., 2007 (17) | Yes | Adults | South Korea | 64 (100) | 0 | 59 (92) | 5 (8) | 0 (0) | 10 mm | 45/67 (67) |
| Wang et al., 2007 (31) | NR | Predominantly adults |
Taiwan | 39 (95) | 7 | 34 (87) | 5 (13) | 0 (0) | NR | NR |
| Janssens et al., 2007 (32) | No | Adults | Switzerland | 58 (100) | 0 | 57 (98) | 1 (2) | 0 (0) | NR | NR |
| Detjen et al., 2007 (25) | No | Children | Germany | 28 (100) | 0 | 26 (93) | 2 (7) | 0 (0) | 10 mm | 28/28 (100) |
| Ozekinci et al., 2007 (33) | No | Adults | Turkey | 28 (NR) | NR | 26 (93) | 2 (7) | 0 (0) | 10 mm and 15 mm | 23/28 (82) |
| Soysal et al., 2008 (19) | NR | Predominantly adults |
Turkey | 100 (100) | 0 | 80 (80) | 16 (16) | 4 (4) | 5 mm | 80/99 (81) |
| Dosanjh et al., 2008 (34) | Yes | Adults | United Kingdom | 148 (100) | 5 | 128 (86) | 20 (14) | 0 (0) | 10 mm | 98/119 (82) |
NR = not reported; TST = tuberculin skin test.
*
“Industry support” refers to any industry involvement or support (e.g., sponsorship, donation of test kits, participation in advisory boards, and involvement of test developers or ownership of patents).
†
Indeterminate results were not excluded in calculating sensitivity estimates.
‡
Children formed 27% of the sample.